TELA Bio, Inc.

TELA Nasdaq CIK: 0001561921

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355
Mailing Address 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355
Phone 484-320-2930
Fiscal Year End 1231
EIN 455320061

Financial Overview

FY2025

$86.57M
Total Assets
$28.46M
Stockholders' Equity
$-0.83
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 25, 2026 View on SEC
8-K Current report of material events March 24, 2026 View on SEC
8-K Current report of material events March 20, 2026 View on SEC
3 Initial insider ownership report March 11, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC

Annual Reports

10-K March 25, 2026
  • Innovative 'Goldilocks' product combines natural tissue with polymer for superior strength and healing.
  • Strong revenue growth of 16% YoY reaching $80.3 million.
View Analysis

Material Events

8-K Financial Distress March 20, 2026
High Impact
  • TELA Bio has a 180-day window to regain Nasdaq compliance by raising its stock price.
  • The company is actively monitoring its stock price and considering options to resolve the issue.
View Analysis

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.